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ABBREVIATIONS 
AD: Alzheimer’s disease 
APOE, APOE4: apolipoprotein E, epsilon 4 allele 
APP: amyloid precursor protein 
Aβ: amyloid-β 
DAT: dopamine transporter 
DRD3: dopamine receptor D3 
GWAS: genome wide association study 
HWE: Hardy–Weinberg equilibrium 
MAPT: microtubule associated protein tau 
MMSE: Mini-Mental State Examination 
NAHR: non-allelic homologous recombination 
NINCDS/ADRDA: National Institute of Neurological and Communicative Disorders and 
Stroke /Alzheimer’s Disease and Related Disorders Associations 
OR: odds ratio 
PCR: polymerase chain reaction 
RFLP: restriction fragment length polymorphism 
SFA: synergy factor analysis  
SNP: single nucleotide polymorphism  
SLC6A3: solute carrier family 6 (neurotransmitter transporter), member 3 
SV: structural variant 
VNTR: variable number of tandem repeats 
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BRIEF SUMMARY 
The emerging research field in molecular genetics which studies structural genomic variants 
as significant contributors of genomic landscape is dating back 15 years. This work puts 
emphasis on the recently discovered genomic inversion at chromosome locus 17q21.31 from 
the following population genetic and medical points of views:   
(1) The first observation on a structural variants’ distinctive carrier rate in the Roma 
founder population is presented here, reflecting the inversion haplotype distribution as 
a hallmark of Asian ancestry in the Roma ethnicity. Furthermore, our data provide 
evidence that the similar heritage is diminished in the Hungarian population.  
 
(2) These records are supported by a study focusing on the distribution of dopaminergic 
gene variants in the populations above.  
 
(3) Beside the population genetic question a medical genetic aspect is involved by 
investigating the 17q21.31 variant in the light of its potential role in Alzheimer’s 
disease. We present a case–control study which contributes to the growing research 
area of genomic disorders by examining the inversion from a gene–gene interaction 
point of view. Synergism of the inversion related microtubule associated protein tau 
genetic variant with apolipoprotein E status is analyzed. We support previous findings 
that latter is a risk factor of Alzheimer’s disease in the Hungarian population. On the 
other hand the disorder was found independent from the inversion, revealing its 
variability as a risk factor among different populations. At last, we demonstrate that 
carefully chosen statistical methods can uncover false positive epistatis in genetic 
interaction research. 
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INTRODUCTION 
Heritable biological features which define us as individuals or compose us to groups are 
examined by natural sciences. The blueprint of these factors is our genome, a system forming 
dynamically on an evolutionary timescale. Research on genome variants in the past decades 
revealed that significant individual specific changes – sometimes making up a couple of 
hundred kilobases in size – can turn to cumulative within families. Alterations in the genome, 
the rise of a new variant can help the survival of the individual and may have beneficial 
consequences on the adaptability and reproduction. This advantage can increase the variant’s 
occurrence through generations in the population. On the other hand, since the genome is an 
open system, benefits or drawbacks of a variant always depend on boundary conditions. If 
those (e.g. environmental factors) change, the same variant can turn out as a shortcoming 
property, limitating the carriers in terms of fitness. 
Considering from a medical genetic aspect the term variant may stand for a genetic alteration 
involved in disease development. More and more detailed knowledge on human genome 
made it possible to obtain data regarding probable factors of disease. This research field 
evolved parallel but independently with the molecular biological quest for variants which 
build up and characterize populations. In the past few years these two fields merged when 
research projects showed that certain variants are associated to disease only in certain 
populations. Studies now set sight on the possibility to uncover how population related 
genomic background contribute to development of pathology. In the following we provide an 
outlook to studies on mixed populations and the interplay between networks within the 
genome. Considering these aspects in medical research may facilitate to rise above the classic 
resolution of association studies. 
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Structural variants in the human genome 
 
The genome’s large scale structural rearrangements are comprehensively known since they 
are easily recognized by traditional cytogenetic methods as fluorescent in situ hybridization. 
Their discovery was early since they result in significant consequences regarding phenotype. 
Chronologically research focus then jumped to the other end of the variant size scale: single 
nucleotide variability guided the focus of interest since sequencing of human genome started. 
These two, especially single nucleotide polymorphisms (SNP) were studied extensively in the 
past decades, and majority of whole genome association studies were also based on single 
nucleotide variants (Sullivan et al., 2012).  
There were great expectations to reveal the genetic background of common disorders by 
defining their genetic architecture. However the germline variants discovered by genome 
wide association studies (GWAS) explained only a small fraction of the traits which led to the 
issue of “missing heritability” (Manolio et al., 2009). It became obvious that common SNPs – 
variants which are present in the population with at least 5% frequency – give only a fraction 
of variability in the genome. Mapping all of the alternations is required to carry out a 
comprehensive study of genetic basis of phenotype. From 2006 it has turned out to be clear 
that variants of the genome build up a continuum from SNPs to larger rearrangements 
(Raphael, 2012).  
Because of technological gaps, structural variants (SVs) ranging from 50 basepairs to 
megabases in size remained hard to find. Until 2007 genomic technologies had a bias toward 
typing unique tags (Baker, 2012), only after the development of array detection methods as 
microarray-based comparative genome hybridization and high-throughput pair-end 
sequencing was it possible to identify structural variants including insertions, duplications, 
deletions, inversions, recurring mobile elements covering more than 50 base pairs (see Table 
1) 
Although structural variants were first assumed as rare elements (e.g. classic cytogenetics 
identified 9 inversions distinguishing humans and chimpanzees), in the past few years it was 
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revealed that the major contributors to human genomic variation are structural variants 
(actually there is an order of 1500 inversions between humans and chimps, shown by Feuk et 
al., 2005). In contrast to SNPs which account for 0.1% of heritable nucleotide differences 
between individuals, SVs are responsible for 0.5-1%. This totals circa 50 megabases per 
genome. Furthermore, investigations considering evolutionary perspective clarified that de 
novo development of structural variants accelerated in primates, and this is clearly outstanding 
in chimpanzee and humans.  
 
Table 1. Spectrum of variations (modified after Sharp, 2006) 
 
Variation Rearrangement type Size range 
Single base pair Single nucleotide polymorphism, point 
mutation 
1 bp 
Small insertion/ 
deletion 
Binary insertion/ short sequence deletion 1 – 50 bp 
Short tandem repeat Microsatellites, simple repeats 1 – 500 bp 
Fine-scale structural  
variation 
Deletions, duplications, tandem repeats, 
inversions 
50bp – 5Kb 
Retroelement insertion Interspersed elements, long terminal repeat, 
endogenous repeat virus 
300 bp – 10 Kb 
Intermediate-scale 
structural variation 
Deletions, duplications, tandem repeats, 
inversions 
5 Kb – 50 Kb 
Large scale structural 
variation 
Deletions, duplications, tandem repeats, 
inversions 
50 KB – 5 Mb 
Chromosomal variation Euchromatic variants, deletions, duplications, 
translocations, inversions, aneuploidy 
5 MB – entire 
chromosomes 
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The high rate of their presence in the genome can be the result of so called genomic hotspots 
which are involved in the development of structural variants. SVs can emerge as a 
consequence of DNA recombination, replication and repair associated processes.  
In Figure 1 non-allelic homologous recombination (NAHR) is illustrated. This is the major 
mechanism involved in the development of genomic rearrangements of human genome.  
 
 
 
 
Figure 1. Deletion, duplication and inversion evolved via NAHR 
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In some cases non-homologous end-joining, mobile element insertion and Fork Stalling and 
Template Switching models shape these rearrangements (Weischenfeldt et al., 2013). 
 
Depending on the recombination process structural variants can be differentiated as 
unbalanced variations characterized by quantitative change in genome material or balanced 
variations which do not result in genomic mass alteration.  
Inversions are balanced structural variations and evolve if NAHR take place between 
segmental duplications or highly identical sequences of inverted orientation. These structural 
variants are extremely complicated to detect. Although the first evidence on a chromosomal 
inversion was published in 1921 by Alfred Sturtevant, uncovering submicroscopic inversions 
is still a challenge, as inversions cannot be detected via arrays. Recently, with pair end 
sequencing their discovery has accelerated but the number of inversions found is still 
insignificant compared to CNVs (Baker, 2012).  
 
After overcoming the difficulties of detection, it is even harder to interpret them in respect to 
their functional consequences. The first notion that genomic structural variants are involved in 
common diseases dates back to 1998, when the term “genomic disease” was used for the first 
time (Lupski, 1998). Since then and especially in the past 5 years several studies testified the 
role of CNVs in complex genomic disorders (with a prominence in mental disorders). Despite 
this progress, our knowledge on inversion related phenotypic variants is still very restricted. 
Beside the detection-bias this can be partially because in contrast to CNVs even large 
inversions can remain neutral on phenotype since there are no dosage imbalances.  On the 
other hand, there is an intriguing question on inversions which clearly points toward their 
significance: if an inverted chromosome has the same genetic information as its pair, why 
does it spread in the population (Kirkpatrick, 2010)? 
A key point to consider is that inversions evolve by leaving breakpoints. Several examples 
show that inversions can lead to the genetic consequences by their positional effect (see 
Figure 2). By disturbing the architecture of the genome by their breakpoint, they can affect 
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coding regions or interrupt transcriptional regulation, even inducing over- or ectopic 
expression and accelerate the emergence of further variants. 
 
 
 
Figure 2. Functional consequences of an inversion through positional effect 
A: Normal genomic landscape where gene-expression is tuned by regulatory elements 
B: After an inversion event all coding regions may remain intact without any quantitative imbalances. 
However the inversion tumbles up the sequence leading to altered expression 
 
Similarly, the role of inversions in disease is sometime not directly causative, rather increase 
the risk of further rearrangements that cause disease. Disease associated genomic 
rearrangements can be recurrent with fixed breakpoint; or non-recurrent with a minimal 
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region of overlap which is associated strongly to the locus conveying the disorder (Feuk, 
2010). Furthermore, inversions also differ from other structural variants as recombination is 
suppressed among heterokaryotypes. 
Research on 17q21.31 in Alzheimer’s disease 
 
A good example regarding the multifaceted nature of inversions is demonstrated by the 
research on one of the most dynamic and complex region of the human genome the 17q21.31 
locus. Among other genes this region codes microtubule-associated protein tau (MAPT), 
which is widely studied, as it contributes to several human diseases (Hardy et al., 2006). The 
main function of microtubule associated protein tau (MAPT) is to maintain the cellular 
structure and morphology (Avila, 2006) in neurons. Beside physiological function, tau protein 
is much more investigated as the core element of neurofibrillary tangles, the major hallmark 
of neurodegenerative disorders, especially Alzheimer’s disease (AD). Certain variants and 
mutations of MAPT gene are more likely disposed to tau protein hyperphosphorylation, 
leading to the development of tauopathies as a consequence of neurofibrillary tangle 
formation. The 900 Kb inversion at 17q21.3 is one of the most notable structural variants 
found to date. Since its identification in 2005 (Stefansson et al., 2005) it is in the centre of 
research interest, as it encompasses several genes (Kalinderi et al., 2009). By this inversion 
two non-recombining major MAPT allele forming haplotypes (H1 and H2) can be 
differentiated (see Figure 3) which affect MAPT related pathomechanisms in distinctive 
manners.  
The extensive investigations revealed that out of the two main non-recombining MAPT locus 
haplotypes H1 plays a role in the development of sporadic tauopathies (Laws et al., 2007) 
while H2 is involved in a neurodevelopmental disorder.  
H2 can lead to a disorder-related phenotype with germline breaking mechanisms which were 
clarified in the past 3 years. The most studied H2 haplotype associated neurodevelopmental 
disorder is Koolen De Vries syndrome. In this case the H2 haplotype (H2D subhaplotype) 
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provide possibility to the development of a causative microdeletion event, encompassing 
MAPT and leading to mental retardation. 
 
 
  
 
Figure 3. The architecture of H1 and H2 17q21.31 regions 
 
The H2D inversion result in a genomic architecture which give rise to NAHR (Shaw-Smith et 
al., 2006) and consecutive microdeletion. The disorder therefore limited to H2 and cannot 
appear in H1 carriers.  
According to recent publications H2 was found to be the more ancient haplotype (Zody et al., 
2008) and in spite of its association to the Koolen De Vries syndrome it is a target of positive 
selection in Europe since H2 carrier women have higher recombination rate with higher 
reproductive success (Stefansson et al., 2005).  
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Regarding H1 other effects can take effect making H2 as the protective haplotype. The H1 
clade is involved in pathophysiologic processes probably as a consequence of more various 
alternative splicing and expression with clear genetic association to Parkinson’s disease 
(Zabetian et al., 2007), progressive supranuclear palsy (Pittman et al., 2004), argyrophilic 
grain disease (Fujino et al., 2005), corticobasal degeneration (Pittman et al., 2005), 
frontotemporal dementia (Verpillat et al., 2002) and lower regional cerebral gray matter 
volume in healthy individuals (Canu et al., 2009). Its association to Alzheimer’s disease is 
also supported by many findings (Myers et al., 2007) but there are controversial results too 
(Caffrey and Wade-Martins, 2012). The profound question is, however, why some studies 
have refuted this association or found carriage of allele H2 to be a risk factor for 
neurodegenerative disorders (Ghidoni et al., 2006, Russ et al., 2001)?  
An explanation for the controversy could be the possible epistatis or interactions of different 
disease specific susceptibility genes. Inversions affecting regulatory element can lead to loss 
of autoregulation or disturbed interaction with other genes (see Figure 4 on next page).  
In complex disorders such as tauopathies, single gene association studies often lead to 
controversial results because they are not sensitive enough to reveal the role of a gene with 
limited effect. As an example, leaving out of consideration the interaction of the major 
pathways implicated in the pathogenesis of Alzheimer’s disease may lead to type 2 errors 
(Combarros et al., 2009). In order to find a suitable model for sporadic complex disorders (as 
late onset Alzheimer’s disease), genetic association studies with special emphasis on the 
synergistic effects of disease associated genes should be performed (Corder et al., 2006). 
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Figure 4. Positional effect resulting in impaired autoregulation and loss of epistasis 
Normal gene autoregulation (A) or genetic epistasis (B) results in a ratio of proteins which form 
complexes in a balanced manner. Inversions (C and D) disintegrate the genomic architecture 
disturbing regulatory elements and initiating cascades in biological pathways. 
 
A B 
C D 
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Another answer to the issue might lie in the notable difference in the ethnical distribution of 
the two main haplotypes. H2 haplotype is rare in Africans, and almost absent in East Asians 
and Native Americans, but very frequent (20–30%) in populations of European Caucasian 
origin (Evans et al., 2004, Stefansson et al., 2005). While in the beginning it has even been 
postulated that the H2 haplotype was contributed to the human genome by Homo 
neanderthalensis (Hardy et al., 2005), broad evidence support now that H2 emerged in 
Eastern or Central Africa and was replaced by H1 cca. 2.3 million years ago in the Homo 
ancestral populations.  H2 later expanded exclusively and rapidly in the European out-of-
Africa populations and became Caucasian-specific (Donelly et al., 2010, Steinberg et al., 
2013). 
A few centuries ago humans opened a new, exciting chapter in their genetic history by leaving 
their geographical environment with accelerated migration and changed it to an unfamiliar 
one in evolutionary extremely short time. In the new milieu the genomic architecture which 
was adapted and fine tuned to the environmental triggers for thousands of years might face 
novel triggers which induced detoriation in homeostasis. The consequence can be population 
specific risk factor of disorders or altered response to treatment (Yang et al., 2011).  
The new developments in large scale genome sequencing (e.g. 1000 Genomes Project, 
http://www.1000genomes.org) provided an opportunity to generate geographical maps of the 
frequency of structural variants. Some of them are typical for different ethnic groups or for 
certain populations (Gu et al., 2007, O'Hara, 2007, Spielman et al., 2007). The presence of 
these variations is thought to be an important contributor to the evolution in human genetic 
diversity and can generate difference in disease susceptibility (Feuk et al., 2006). Thus, 
medical genetic studies with a special focus on population genetics started to examine 
admixed population as a form of disease associated gene-discovery (Seldin et al., 2011). 
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The intriguing genetic history of two populations in the Carpathian basin 
 
In this work two historically and ethnically different populations (Roma/Gypsies and 
Caucasian Hungarians) are examined from the same geographical area. The Caucasian 
Hungarians belong to the Uralic linguistic family, a diverse group of people related by an 
ancient common linguistic heritage, distinct from that of the Indo-European speakers who 
surround them. Of the approximately 25 million Finno-Ugrians, the best known are the 
Estonians, the Finns and the Hungarians. Around the 5th century BC, the ancient Hungarians 
were caught up in a wave of migrations that swept the steppes and were displaced from their 
western Siberian homeland. Migrating westwards, the Hungarians arrived in 895 in the 
Carpathian Basin, an area where the overwhelming majority of the indigenous population was 
Slavic. Various genetic appraisals have estimated that the newly arrived Hungarians 
accounted for 10–50% of the total population of the Carpathian Basin (Cavalli-Sforza et al., 
1994). During the turbulent history of present-day Hungary, the mixing process has 
continued, and Hungarians can now be regarded as members of a mixed European population 
(Semino et al., 2000). In contrast to Hungarians, Roma are a conglomerate founder population 
with Asian Caucasian roots, imbedded in a genetically different European Caucasian 
population. The social sciences and comparative linguistic studies have hinted at the Asian 
origin, and this has been supported by population genetic studies of single-locus 
polymorphism, of multi-locus STR Y chromosome haplotypes and of mtDNA haplotypes 
(Gresham et al., 2001, Kalaydjieva et al., 2001a, Morar et al., 2004,  Rai et al., 2012, 
Mendizabal et al., 2012). The most recent study investigated Roma SNP data in 6 populations 
(Moorjani et al., 2013). They revealed that in present-day Roma populations’ characteristics 
of Eastern-European and North-Western Indian heritage can be revealed. The estimated time 
of the founder event occurred about 27 generations (~800 years) ago. The combined evidence 
suggests that Roma migrated from Punjab region of Northwest India 1000–1500 years ago 
and traveled through Asia (along Persia, today’s Armenia and Turkey). The main stream 
moved into the Balkans and Greece and some of them into Eastern Europe ahead of the Turks. 
Early diaspora appeared in western Europe around the period from the fourteenth to the 
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fifteenth century, and another wave of migrations to western Europe started after the abolition 
of serfdom in the Habsburg Empire in 1841, and recently from 1989 after the disappearance 
of the Iron Curtain (Kalaydjieva et al., 2005). 
At present, 8–10 million Roma live in fragmented subisolates in Europe, approximately 
600000 of them in Hungary. In Roma society, the primary unit is the group, and groups are 
members of metagroups. They live in a closed society structure, with rare admixture with 
other populations, and a relatively high rate of consanguinity (Assal et al., 1991). There 
appears to have been population bottlenecks, both when they left India and during the 
European segregation. A high intragroup diversity can be observed (Gresham et al., 2001). 
Hungarian Roma were not classified in previous publications or were included among western 
European Roma/ Gypsies (Morar et al., 2004). However, we think that the comparison of the 
Hungarian Roma population is an adequate choice for genetic investigations because the 
ethnic diversity in Hungary is not as high as in the Balkans, and it is possible to distinguish 
three well-described metagroups among Hungarian Roma. Carpathian Roma or Romungros 
are the least characterized and intact metagroup. Their language consists elements from Beas, 
Lovari and Hungarian. They represent the 70% of the Roma living in Hungary. 
The two smaller metagroups are more closed and cohesive; they live typically in separated 
parts of smaller villages or towns. They preserve their traditions and language; as a 
consequence, the assimilation with other metagroups or with the Caucasoid Hungarian 
population is low. Beas represents 10% of the Hungarian Roma population; their migration to 
the Carpathian Basin came from the Central-West Balkans. They speak the Beas language. 
The Olahs, with a proportion of 20% from the Hungarian Roma population, arrived at the 
Carpathian Basin from the territory of today’s Romania and they speak the Lovari language. 
They are the descendants of the Valachian/Vlax Roma, the most studied Roma population 
(Kalaydjieva et al., 2001a). 
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Genetic variants in the Roma population 
 
We have limited information on the spectrum of genetic variants in the Hungarian Roma 
population. Most of data available focuses on SNPs and there are several founder effect 
associated, clinically relevant findings from Hungarian research groups (e.g. Sipeky et al., 
2009, 2013). On the other hand, SVs are barely investigated. Although the published genetic 
research on Roma populations is fragmentary so far, it indicates that medical genetics can 
have an important role in improving the health conditions and health statistics of the Roma 
population. Several mendelian disorders and private mutations have been identified, but the 
distribution of alleles that lead to genetically complex diseases have not been studied 
systematically in the Roma (Kalaydjieva et al., 2001b). There is a need for further research, 
because no exact data are available on the prevalence of psychiatric diseases or the genetic 
background of these disorders in the Roma population.  
In this work primarily we aimed to investigate the 17q21.31 structural variant. In a satellite 
study, supporting our goal, variants representing other rearrangement types are also included. 
Since complex mental disorders make up our main area of interest, candidate genes of 
dopaminergic pathways were investigated.  
Dysfunctions of the dopaminergic system occur in several neuropsychiatric disorders, such as 
schizophrenia, bipolar affective disorder, drug abuse and Parkinson’s disease (Cousins et al., 
2009, Halliday and McCann, 2010, Lodge and Grace, 2011). The susceptibility to these 
disorders can be mediated by variants of genes involved in dopaminergic transmission, i.e. 
dopamine transporter and dopamine receptors (Hoenicka et al., 2007). The dopamine 
transporter (DAT) gene (SLC6A3) 40 bp variable number tandem repeat (VNTR) and the 
dopamine D3 receptor (DRD3) Ser9Gly polymorphisms have been widely studied for 
population variations, but until now the Roma population was not examined for these 
markers. DAT is responsible for the presynaptic reuptake of dopamine and it is also the target 
of several psychoactive drugs (Kang et al., 1999). The human SLC6A3 gene is located on 
chromosome 5p15.3 and a 40 bp VNTR polymorphism has been identified in the 3’ 
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untranslated region (Sano et al., 1993). The diverse physiological functions of dopamine are 
mediated by five different dopamine receptors. The D1 and D5 receptors are members of the 
D1-like family of dopamine receptors, whereas the D2, D3 and D4 receptors are members of 
the D2-like family. DRD3 is predominantly expressed in limbic brain areas which are altered 
in several psychiatric disorders (Bouthenet et al., 1991). The DRD3 gene has been mapped to 
chromosome 3q13.3. A single-nucleotide polymorphism (SNP) in the 5’ part of the DRD3 
gene producing a non-conservative amino acid substitution at codon 9 (Ser/Gly) has been 
identified (Lannfelt et al., 1992).  
 
  
21 
 
AIMS 
I 
The first aim of this work was to investigate the allocation of 17q21.31 related genomic 
inversion haplotypes in Hungarian Roma populations. Since they are Asian in origin our 
hypothesis was that the frequency of Caucasian-specific H2 haplotype is low as a result of 
closed Roma societies. The control population was Hungarians where previous studies 
showed lack of genetic heritage reflecting the Asian roots. 
II 
The second goal was to carry out an independent satellite investigation on a larger group and 
study well-characterized genomic variants to support our findings in the previous study. The 
present study provides the first data about the SLC6A3 40 bp VNTR and the DRD3 Ser9Gly 
polymorphisms in Roma population in Hungary. 
III 
Third, the region of our interest is controversially related to complex psychiatric disorders, 
that is, tauopathies. Since the region’s structure show great variability in different populations, 
we found it important to examine its relation to Alzheimer’s disease in the Hungarian 
population. Moreover, we extended this study to examine the genetic interaction with the 
widely replicated apolipoprotein E epsilon 4 (APOE4) allele. Considering the convergence of 
their biological pathways (Adalbert et al., 2007), we examined the possible interaction of tau 
H1 haplotype and APOE4 in the Caucasian Hungarian population. 
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METHODS 
Study I  
Sample characteristics 
In this study, 118 healthy Roma of the Olah/Vlax metagroup and 184 healthy Caucasian 
Hungarians were genotyped. The Roma participants were recruited from three villages in the 
same geographical area in northeastern Hungary. The Hungarians were employees and 
students of Department of Psychiatry, University of Szeged, and Department of Hungarian 
Congenital Abnormality and Rare Disease Registry of the National Centre For Healthcare 
Audit and Improvement and their acquaintances, who were matched with the Roma 
volunteers for age and gender. After complete description of the study to the subjects, written 
informed consent was obtained.  
DNA isolation 
The genomic DNA of Roma and control subjects was extracted from peripheral blood 
according to a standard method (Davies, 1993). 
Genotyping 
In this study, our goal was to evaluate the H1–H2 haplotype frequencies in the populations 
mentioned above by using a polymorphism of MAPT gene as a marker. The selected region 
was amplified by the means of the PCR. The inverted chromosome region was screened by 
applying the standardly used biallelic intron 9 deletion-inversion polymorphism (Baker et al., 
1999). The following primer pairs were used: forward: 5’-
GAAGACGTTCTCACTGATCTG-3’; reverse: 5’-AGGAGTCTGGCTTCAGTCTC-3’. 
Polymerase chain reaction amplification was carried out in 20 µl reaction volume containing 
2 µl of 10xZenonBio, 10x reaction buffer, 50 nM of each of the primers, 0.5 mM of each of 
the dNTPs, 4 mM MgCl2, 100 ng of DNA extract and 0.3U of ZenonBio TaqPolymerase. The 
amplification protocol was as follows: 3 min at 93 °C, 30 cycles of 93 °C for 60 s, 60 °C for 
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60 s and 72 °C for 60 s, and final extension at 75 °C for 5 min. A volume of 7 µl of PCR 
product was run on 6% native polyacrylamide gel and visualized after ethidium bromide 
staining by UV transillumination, and the size of the products was determined with the 
gelBase gel documentation system (UVP).  
Statistical analysis 
The departure from the Hardy–Weinberg equilibrium was tested by using the ‘HWE.test’ 
function (P-value calculated by the exact method) of the genetics R package (R version 2.4.0, 
R Development Core Team, 2006; Warnes, 2008). Fisher’s exact tests carried out in R were 
used to determine the significance of differences in genotype and allele frequencies. 
Study II 
Sample characteristics 
The study included 189 Olah Roma and 189 Hungarian Caucasian healthy probands from 
Hungary. The mean age (±SD) for the Olah Roma group was 38.3 (±13.2) years, and for the 
Hungarian group 45.1 (±16.1) years. The male/female ratio was 76/113 in the Olah Roma and 
82/107 in the Hungarian group. Informed consent was obtained from the subjects and all 
protocols were approved by the Ethics Committee of the University of Szeged.  
DNA isolation 
DNA was extracted from peripheral blood leucocytes according to a standard procedure using 
the Roche High Pure PCR Template Preparation Kit (Roche Applied Science, Basel, 
Switzerland).  
Genotyping 
SLC6A3 40 bp polymorphism genotyping was made by polymerase chain reaction (PCR) as 
described earlier (Sano et al., 1993). Genotyping of the DRD3 Ser9Gly polymorphism was 
conducted by PCR amplification and then enzymatic digestion with the restriction enzyme 
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MscI, followed by polyacrylamide gel electrophoresis with ethidium bromide staining 
(Lannfelt et al., 1992).  
Statistical analysis 
The statistical analyses were performed by using SPSS 15.0 for Windows software (SPSS, 
Chicago, USA). The significance level for all statistical tests was set at 0.05. The Pearson’s χ2 
test was used to compare the SLC6A3 and DRD3 genotypes and the SLC6A3 allele 
frequencies between the Olah Roma and Hungarian groups, while Fisher’s exact test was 
applied to assess DRD3 allelic differences between the two investigated populations. Hardy–
Weinberg equilibrium (HWE) for the distribution of SLC6A3 and DRD3 genotypes was 
estimated by Pearson’s χ2 test. 
Study III  
Sample characteristics  
One hundred and seventy-four Caucasian probands participated in our study from the 
Southern Hungarian Region. The 91 AD (mean age / SD, 69.5 / 11.9 years; male/female 
40/51; MMSE score / SD, 14.1/ 4.9 points) patients were randomly selected from the 
outpatient population of the University of Szeged Memory Clinic. The clinical diagnosis of 
late onset sporadic AD was based on the ICD-10 and the generally accepted criteria of the 
National Institute for Neurological and Communication Disorders and Stroke/Alzheimer's 
Disease and Related Disorders Association (NINCDS-ADRDA). The AD probands were 
considered sporadic type, because none of them had a family history of dementia. All patients 
underwent CT and MRI studies (in some dubious cases diagnose was confirmed by SPECT) 
in order to exclude any other neurological disorder. The 83 healthy control persons (mean age 
/ SD, 67.4 / 12.3 years; male/female 42/41; Mini-Mental State Exam (MMSE) score ≥ 28 
points) were spouses of the AD probands and none of them had verified symptoms of 
dementia. All the participants gave their informed consent to the study, which was approved 
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by the local ethics committee. The study was conducted according to the Declaration of 
Helsinki and subsequent revisions. 
DNA isolation 
The genomic DNA of AD and control subjects was extracted from peripheral blood according 
to a standard method (Davies, 1993).  
Genotyping 
MAPT genotyping is described in Study I (Almos et al., 2008). APOE alleles (E2, E3, and 
E4) were determined by previously described polymerase chain reaction-based strategy 
(Kalman et al., 1997). Briefly, PCR reaction was performed in a PTC 100, Thermal Controller 
MJ Res. Inc. thermal cycler. The final volume of PCR solution was 25 µl, containing 20 µM 
of two primers (5’-TCCAAGGAGCTGCAGGCGGCGCA-3', and 5’-
ACAGAATTCGCCCCGGCCTGGTACACTGCCA-3'), 1.25 µl from each, 50-300 ng of 
genomic DNA, 1.25 µl of dNTPs (20 mM), consisting a mix of 5 mM of each, 1.5 µl (25 
mM) MgCl2, 2.5 µl (5%) dimethyl sulfoxide, 0.5 U of TaqDNA polymerase (Promega), in 67 
mM TRIS-HCl buffer (pH 8.8). The initial denaturation was 5 min at 95°C, followed by 30 
cycles of 30 s at 94°C denaturation, 22 s at 63°C annealing and extension for 30 s at 72°C. A 
final extension for 3 min at 72°C completed the amplification procedure. The amplified DNA 
was digested with 5 U CfoI (Promega) overnight at 37°C, and the DNA fragments (91, 81, 72, 
48 base pairs) were separated on 8% non-denaturing acrylamide gel. The gel was stained with 
0.5 µg/ml ethidium bromide, and APOE genotype was determined by the pattern of DNA 
fragments present.  
Statistical analysis  
Age and MMSE scores were normally distributed (according to Kolmogorov-Smirnov test) 
and compared by independent samples t-test. Variances of MMSE scores were unequal 
(according to Levene’s test), therefore it was compared with Welch’s t-test. Alleles and 
genotypes were counted and their distribution between the groups was compared by Pearson 
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χ2 test. The data were analyzed using SPSS for Windows (version 12.0). χ2 effect sizes and 
power calculation were estimated by PASS
 
2008 software. Since small sample size is limiting 
the power of the study, the examination of gene interaction was carried out by the mean of 
synergy factor analysis (SFA) (Combarros et al., 2009). Based on logistic regression, SFA can 
be used as a method which provides statistically reliable data in case of limited number of 
participants. Power calculations for expected synergy factors were estimated by the statistical 
software R (v. 2.8.1) with the script “SFProgrammes.r”, provided by Mario Cortina-Borja 
(Cortina-Borja et al., 2009). 
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RESULTS 
Study I 
The MAPT allele frequencies in the Caucasian sample were in Hardy–Weinberg equilibrium 
(P=0.842). A deviation from the Hardy–Weinberg equilibrium was observed in the Roma 
population sample (P=0.017). The distribution of MAPT genotypes are presented in Figure 5. 
The MAPT H1 homozygote haplotype is seen to be overrepresented in the Roma as compared 
with the Caucasians (83.0% (n=98) vs. 56.5% (n=104) one-tailed P<0.001). H1/H2 
heterozygotes prevail in the Caucasian population (38.0%; n=70 in the Caucasians vs. 13.6%; 
n=16 in the Roma) (one-tailed P<0.001). The calculated frequency of the H1 allele in the 
Roma population was greater than that in the Caucasians (89.8% (n=212) vs. 75.5% (n=278) 
(one-tailed P<0.001), whereas H2 allele was more dominant in the Caucasian population.  
 
 
Figure 5. Ethnicity dependent MAPT genotype distribution 
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Study II 
Genotype and allele distributions of SLC6A3 40 bp VNTR polymorphism are shown in Table 
2 and 3. In this polymorphism the different alleles are determined by the copy number of a 40 
bp long DNA segment in the 3’ untranslated region of the SLC6A3 gene. Four types of 
SLC6A3 alleles were found in this study: the eight-repeated (A8), the nine-repeated (A9), the 
ten-repeated (A10) and the eleven-repeated (A11) alleles. In the Olah Roma group no A8 
allele carriers were detected, while we found only one person with A8/A10 genotype among 
the Hungarians. The frequency of the A9/A10 genotype was significantly higher in the 
Hungarian population as compared to the Olah Roma group (Roma, 23.8%; Hungarian, 
43.9%). The frequency of the A10/A11 genotype was significantly higher in the Olah Roma 
population than in Hungarians (Roma, 8.5%; Hungarian, 1.6%). The A10 allele occurred with 
similar frequency in the two populations (Roma, 72.2%; Hungarian, 70.6%). In contrast, the 
occurrence of the A9 allele was significantly lower, whereas the A11 frequency was 
significantly higher in the Olah Roma population than in the Hungarian probands (A9: Roma, 
20.4%; Hungarian, 28.0%; A11: Roma, 7.4%; Hungarian, 1.1%).  
The DRD3 Ser9Gly genotype and allele frequencies are presented in Table 4 and 5. 
Comparison of DRD3 genotype frequencies between the Olah Roma and Hungarian groups 
showed no significant difference, although the frequency of the Ser9Ser homozygous 
genotype was numerically lower and the frequency of the Ser9Gly genotype was numerically 
higher in the Olah Roma than in the Hungarian population (Ser9Ser: Roma, 42.9%; 
Hungarian, 50.3%; Ser9Gly: Roma, 52.9%; Hungarian, 45.0%). The Gly9Gly genotype 
occurred with similar frequency in the two populations (Roma, 4.2%; Hungarian, 4.7%). 
Similarly, there were no statistical differences in the occurrence of DRD3 alleles in Olah 
Roma population as compared to the Hungarians (Ser9: Roma, 69.3%; Hungarian, 72.8%; 
Gly9: Roma, 30.7%; Hungarian, 27.2%). The SLC6A3 and the DRD3 genotype frequencies 
were in HWE in the Hungarian group (SLC6A3, P=0.548; DRD3, P=0.065), while a 
deviation from the HWE was detected in the Olah Roma population (SLC6A3: P<0.001; 
DRD3: P=0.001).  
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Table 2. Dopamine transporter genotype frequencies 
Genotypes* Roma  
n=189 
Hungarian 
n=189 
    A8/A10 - 1 (0.5%) 
    A9/A9 15 (7.9%) 11 (5.9%) 
    A9/A10 45 (23.8%) 83 (43.9%) 
    A9/A11 2 (1.1%) 1 (0.5%) 
    A10/A10 106 (56.1%) 90 (47.6%) 
    A10/A11 16 (8.5%) 3 (1.6%) 
    A11/A11 5 (2.6%) - 
*χ2=28.431 (6), P<0.0001 
 
Table 3. Dopamine transporter allele frequencies 
Alleles** Roma 
n=189 
Hungarian 
n=189 
   A8 - 1 (0.3%) 
   A9 77 (20.4%) 106 (28.0%) 
   A10 273 (72.2%) 267 (70.6%) 
   A11 28 (7.4%) 4 (1.1%) 
** χ2=23.662 (3), P<0.0001 
 
Table 4. Dopamine D3 receptor genotype frequencies 
Genotypes* Roma  
n=189 
Hungarian  
n=189 
     Ser9Ser 81 (42.9%) 95 (50.3%) 
     Ser9Gly 100 (52.9%) 85 (45.0%) 
     Gly9Gly 8 (4.2%) 9 (4.7%) 
*χ2=2.389 (2), P=0.303 
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Table 5. Dopamine D3 receptor genotype frequencies 
 
 
 
 
 
 
** Fisher’s exact P=0.336 
 
Table 6. Dopamine transporter gene and dopamine D3 receptor allele frequencies in 
different populations 
 European Caucasian Indian origin Indian 
SLC6A3 Swedish
*
 French 
Canadian
*
 
Hungarian
* 
Roma
* 
North Indian
#
 
DRD3  Jönsson et 
al., 1993 
Joober et al., 
2000 
Present 
work 
Present work Prasad et al., 
2008 
   A8 - -   0.3% - - 
   A9 - 25.5% 28.0% 20.4% - 
   A10 - 74.5% 70.6% 72.2% - 
   A11 - - 1.1% 7.4% - 
      
   Ser9 72% 71% 73% 69% 64% 
   Gly9 28% 29% 27% 31% 36% 
*
 healthy probands, 
#
 type-2 diabetes subjects 
Alleles** Roma  
n=189 
Hungarian  
n=189 
     Ser9 262 
(69.3%) 
275 
(72.8%) 
     Gly9 116 
(30.7%) 
103 
(27.2%) 
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Study III  
There was no significant difference between the mean ages of the two groups (t=-0.424, 
df=158, P=0.672). MMSE scores of the patient group were significantly lower than those of 
the control group (Welch’s t=25.948, df=79.829, P<0.0001). MAPT and APOE allele 
frequencies were in Hardy–Weinberg equilibrium both in control (MAPT χ2=0.009, df=1, 
P=0.99), (APOE P=0.93, χ2=1.36, df=5) and AD samples (MAPT χ2=0.06, df=1, P=0.97), 
(APOE χ2=5.33, df=5, P=0.38). χ2 effect sizes were small regarding all MAPT genotypes 
(χ2=1.03, df=2, P=0.59), MAPT alleles (χ2=0.97, df=1, P=0.32) and APOE4 state (χ2=4.01, 
df=1, P=0.03). Our sample size of 91 patients and 83 controls achieves 65% power to detect 
the widely accepted effect size of 0.2 using a 2 degrees of freedom Chi-square Test with a 
significance level of 0.05 (Cohen, 1988). 
 
 Table 7. MAPT and APOE genotype and allele frequencies in patients and controls 
 
 
 
 
MAPT MAPT APOE4 
H1/H1 H1/H2 H2/H2 H1 H2 + - 
AD 60.4% 35.2% 4.4% 78% 22% 34.1% 65.9% 
(n=91) (55) (32) (4) (142) (40) (31) (60) 
 
Ctrl 54.2% 38.6% 7.2% 73.5% 26.5% 20.5% 79.5% 
(n=83) (45) (32) (6) (122) (44) (17) (66) 
 χ2=1.03,df=2, P=0.59 χ2=0.97, df=1, P=0.32 χ2=4.01, df=1, P=0.03 
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However the SFA can be applied to datasets of any size, its power calculation could be carried 
out only on H1 homozygotes with the preliminary script (see Table 9 and Figure 6). Table 7 
represents allele and genotype frequencies of MAPT and proportions of APOE4 carriers. No 
significant differences can be observed in the distribution of MAPT genotypes or allele 
frequencies in AD patients as compared with control individuals. The calculated frequency of 
the H1 allele in the AD population did not differ significantly from that in the controls. The 
allele frequency of APOE4 was significantly higher in the AD sample. The individuals with 
the combination of at least one APOE4 allele with at least one H1 allele were overrepresented 
in the AD sample if compared to other participants of the group (30.8%, n=28 vs. 14.5%, 
n=12, χ2=6.52, df=1, P=0.011). 
Table 8 represents synergy factor analysis. SF values are 1.02 if H1/H1 genotype and 5.42 if 
H1 allele is considered to act as a risk factor: neither H1 allele, nor H1/H1 genotype obtain 
statistically significant interaction with APOE4.  
 
Table 8. Synergy factor analysis of MAPT and APOE4 in different constellations 
 
 
MAPT H1/H1 APOE4 Controls AD OR SF, Z, p 
- - 31 25 Reference  
+ - 36 35 1.205  
- + 7 12 2.126  
+ + 9 19 2.618 SF=1.02, 
Z=0.03, 
P=0.98 
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Table 8 (cont’). Synergy factor analysis of MAPT and APOE4 in different constellations 
      
MAPT H1 APOE4 Controls AD OR SF, Z, p 
- - 2 2 Reference  
+ - 65 58 0.89  
- + 4 2 0.5  
+ + 12 29 2.41 SF=5.42, 
Z=1.23, 
P=0.22 
 
 
 
Table 9. SFA power values at different sample sizes 
 
SF        n=83             n=87             n=91            n=100 
1 0.03959 0.04648 0.05084 0.04835 
1.5 0.14111 0.14048 0.14826 0.15167 
2 0.25060 0.25080 0.27140 0.27718 
2.5 0.36201 0.35936 0.38309 0.40357  
3 0.45463 0.45478 0.48740 0.50839 
3.5 0.53686 0.54299 0.57182 0.60346 
4 0.60659 0.61699 0.64347 0.67547 
4.5 0.67363 0.68858 0.68587 0.74047    
5 0.74067 0.76017 0.72827 0.80546 
5.5 0.80772 0.83176 0.77067 0.87045   
6 0.87476 0.90335 0.81307 0.93545 
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Figure 6. SFA power curves at different sample sizes 
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DISCUSSION 
Our results indicate a different proportion of the inversion at 17q21.3 in Olah Roma as 
compared with Caucasian Hungarians. This study has revealed that Olah Roma, who are 
related to the Asian population, carry the H1 allele at a higher proportion than European 
Caucasian populations. This supports the notion that 17q21.3 structural variation and tau 
haplotypes are suitable markers for the demonstration of the degree of admixture in a well-
characterized non–European population. The 24.5% H2 allele frequency in the Hungarian 
population accords well with the frequency of ~25% in Middle Eastern and European 
populations (Evans et al., 2004). The previously reported 8% of H2 allele frequency (Evans et 
al., 2004) in the Finnish population stands closer to the Asian genotype distribution. These 
results suggest that the Finnish population experienced less admixture than the population of 
Hungary, and the Asian descent of the latter is not detectable by this method. 
 
 
 
Figure 7. Routes of migration and frequency of 17q21.31 inversion 
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In our Roma sample, the frequency of H1 allele was lower than previous estimates from 
populations of Asian origin (only populations from South Pakistan were similar) (Evans et al., 
2004). Lower frequency of the H1 haplotype in the Roma population may be a consequence 
of their coexistence for centuries and partial admixture with H2 carrier Caucasian populations. 
This effect is likely to have been strengthened by the fact that the Olah/Vlax metagroup 
traditionally tolerates marriages with non-Roma women, whereas some other Roma groups do 
not. The deviation from the Hardy–Weinberg equilibrium in the Roma group can be explained 
by the population genetic effect of their closed society structure and the higher rate of 
consanguineous mating.  
The Roma ethnic group was ignored for centuries by Western society and medicine. The 
United Nations Development Programme (www.undp.org) and the Decade of Roma Inclusion 
2005–2015 (www.romadecade.org) recognized the importance of medical and social studies. 
In the past decade, various mendelian diseases with a carrier rate of 5–15% have been 
identified in the Roma population (Kalaydjieva et al., 2001b), but multifactorial tauopathies 
have not been well described in Roma. This can be explained by their social and medical 
neglect and the fact that tauopathies are typically late-onset neurodegenerative diseases, 
although the average life expectancy of Roma is 10–15 years lower than the European 
standard (Sepkowitz, 2006).  
Population specific inversion contributes to phenotypic variability and adaptation 
 
The clearest example regarding an inversion’s effect on phenotype can be observed in local 
adaptation and speciation of a plant, the yellow monkeyflower, Mimulus guttatus. This 
species exists in two ecotypes which show distinct differences on flowering time. The one 
which is annual is habituated to dry inlands and flower early, while the other is perennial and 
adapted to moist and cool weather at the coast with flowering later in the year. This ends up in 
premating isolation and also a postzygotic in hybrids. These phenotypic variations are 
attributed to an inversion which suppresses recombination in hybrids and contribute to 
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reproductive isolation between the forms. This is a compelling example on the local 
adaptation hypothesis for inversions (Kirkpatrick, 2010; Lowry & Willis, 2010). 
As described earlier, the 17q21.31 inversion haplotypes show distinct effects on populations. 
H2 carriers are at risk to develop a microdeletion event leading to neurodevelopmental delay 
while in H1 homozygotes this form of replication event is not possible. Therefore, Koolen De 
Vries syndrome (which is accounting for 1% of mental retardations) is exclusively related to 
the Caucasian genome and absent from Asians. Now, first in the literature it is shown that 
Roma populations are at risk to develop this disorder, since owing to the admixture effect they 
carry the H2 allele. 
On the other hand, regarding H1 related pathology the case is not so evident. It was shown 
that H1 carriers are under a negative selection in Europe since H2 carrier women have more 
children (Stefansson et al., 2005, Voight et al., 2006) and because of the possible role of H1 
allele in tauopathies. Alzheimer’s disease (Laws et al., 2007, Myers et al., 2005), Parkinson’s 
disease (Skipper et al., 2004), progressive supranuclear palsy (Pittman et al., 2004), 
argyrophilic grain disease (Fujino et al., 2005), corticobasal degeneration (Buee and 
Delacourte, 1999) and the Parkinson–dementia complex of Guam (Sundar et al., 2007) are all 
associated with MAPT H1 in certain populations. It seems that carrying H1 allele influence 
disease onset via influencing gene expression or alternative splicing. Both may lead to 
enhanced tangle formation and the development of the disease (Avila, 2006, Caffrey et al., 
2006, Hardy et al., 2006, O'Hara, 2007).  
It is well known that exposure to different (that is, European) environmental factors may lead 
to differences in epigenetic effects on gene expression (Spielman et al., 2007). A recent study 
(Winkler et al., 2007) demonstrated H1/H1 genotype as an ethnically dependent risk factor of 
Parkinson’s disease, and another one raised further remarkable suggestions on this field (Fung 
et al., 2005). An early work also observed association regarding tau variants and Asian versus 
Caucasian populations in progressive supranuclear palsy (Conrad et al., 1998). Thus, higher 
H1 frequency in Roma might be a risk factor of multifactorial disorders and be manifested as 
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an elevated susceptibility to tauopathies among the Roma population in Europe. Further 
investigations are needed in populations with high H1 frequency where the social and medical 
aspects and the average life expectancy are better.  
When non-European genetic variants meet European environment 
 
Our study focusing on previously not examined SNP and VNTR variants in Roma populations 
supported our findings on genetic heritage. The results revealed a statistically significant 
difference between Olah Roma and Hungarian populations in the distribution of SLC6A3 
alleles. The frequency of the A9 allele was significantly lower whereas the occurrence of the 
A11 allele was significantly higher in the Olah Roma group as compared to the Hungarian 
population. However, the comparison of the frequencies of the A10 allele showed no 
significant difference. While this is the first report on SLC6A3 polymorphism in the Roma 
population and no data are available from North India where the Roma originate from, several 
other populations have been studied (Joober et al., 2000, Kang et al., 1999, Mitchell et al., 
2000). Kang and co-workers summarize and compare the SLC6A3 allele frequencies of more 
than 1500 individuals from 30 populations in a meta-analysis (Kang et al., 1999). The 
observed alleles show a range from 3 to 12 repeats, but the three-, seven-, eight- and twelve-
repeat alleles occurred only with very low frequency and no four-, five- or six-repeat alleles 
were detected. The A10 allele is the most frequent with some variation in the different 
populations. The second most frequent allele is A9 (Kang et al., 1999, Mitchell et al., 2000). 
These findings are in agreement with our results in the Olah Roma and Hungarian 
populations, as well as with another study investigating the SLC6A3 allele distribution in the 
French–Canadian population (Joober et al., 2000). See Table 6 for comparison. 
The A9 allele was associated with severity of alcohol withdrawal symptoms (Sander et al., 
1997) and reduced risk of tobacco smoking (Lerman et al., 1999) while the A10 allele was 
linked to attention deficit hyperactivity disorder (Cook et al., 1995, Gill et al., 1997) A 
significant genotypic effect on DAT levels was found in a large sample of healthy subjects: 
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the A9 carriers had a significantly higher striatal DAT availability compared to the A10/A10 
homozygotes (van Dyck et al., 2005). On the other hand biological data regarding A11 allele 
is fragmentary so far.  These observations reveal that the genetic variants of SLC6A3 show a 
remarkable difference which may point toward certain neuropsychiatric and addictive 
disorders in the Roma population. Therefore these findings should be considered once 
interventions programs are developed to battle high rates of alcohol and nicotine misuse in 
Roma populations. 
The role of DRD3 Ser9Gly polymorphism is not entirely clarified, but it has been extensively 
investigated and a correlation was found between the Ser9 allele and the response to typical 
antipsychotics, and between the Gly9 allele and the response to atypical antipsychotics in 
schizophrenic patients (Scharfetter, 2004). Another study from our laboratory reported that 
Ser9Ser genotype is associated with worse therapeutic response and more severe dysfunctions 
in schizophrenic patients (Szekeres et al., 2004). There were no statistical differences in the 
occurrence of DRD3 alleles in the Olah Roma population as compared to the Hungarian 
population in our study. Association studies investigating European Caucasian and North 
Indian populations also reported data similar to the pattern observed in the Olah Roma and 
Hungarian populations (Jonsson et al., 1993, Prasad et al., 2008). Only a small difference 
within the limits of the statistical error was found between Europeans and North Indians 
(Prasad et al., 2008). The frequency of the Ser9 allele seems slightly lower in Olah Roma 
people and in the North Indian population as compared to European Caucasians, although this 
difference proved to be statistically non–significant.  
In summary, our results provide evidences about the polymorphisms of the dopamine-related 
genes in a Roma population which deserves further characterization.  
17q21.31 and APOE4 do not act in synergy in AD 
 
The third study contributing to this work is a case–control study, examining the distribution of 
MAPT and APOE4 alleles and the combination of those in Hungarian Caucasian AD samples 
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and healthy controls. The results indicate that in both groups the representation of H1 
haplotype accords well with the frequency of ~75% in Middle–Eastern and European 
populations which was determined earlier (Evans et al., 2004). In this manner MAPT H1 
haplotype can not be identified as a risk factor of AD in the Hungarian population.  
It should be considered why several studies found association to AD and other tauopathies 
(Baker et al., 1999, Fujino et al., 2005, Pittman et al., 2005, Togo et al., 2002, Zabetian et al., 
2007) while ours pertain to those which disprove this association (Russ et al., 2001). 
First, a possible explanation could be that only more specific subhaplotypes of H1 clade may 
play a major role in tauopathies. Regarding AD, recent studies indicated that the promoter 
polymorphism rs242557 delineates a subhaplotype (H1c) which could be the risk factor for 
developing AD (Myers et al., 2007). Though, there are negative replications with H1c too 
(Mukherjee et al., 2007).  Furthermore, cumulating evidences suggest that disorders where the 
diagnosis is based on tau-pathology related stable biomarkers are associated to this genetic 
background. It is well-known that late onset AD is a complex disorder, where tau pathology is 
an important, but not sole contributor to disease process (Caffrey et al., 2012).  
The second issue deserving interest is the interaction of major pathways and biological 
networks implicated in tauopathies. MAPT haplotypes do affect gene expression in tissue 
specific manners (de Jong et al., 2012). Recent studies indicate that hyperphosphorylated tau 
is overrepresented in Parkinson’s disease patients with H1/H1 alleles (Kwok et al., 2005), and 
the activity of tau kinases which are responsible for the phosphorylation of the protein are 
increased in AD (Leroy et al., 2007). The kinases of tau phosphorylation and the connection 
with other major pathways together may constitute the genetic basis of AD. A synergistic 
effect between glycogen synthase kinase-3beta and tau genes was found recently (Kwok et al., 
2008). 
In our study, we examined MAPT haplotypes and APOE4 state as elements of converging 
pathways in the development of AD. This supposition was based on the fact that APOE has a 
broad role in AD pathology with several synergistic connections (Combarros et al., 2009) and 
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has influence on tau phosphorylation (Tesseur et al., 2000). Recently further evidence showed 
that APOE status comprises a network of connections with APP and MAPT predisposing to a 
molecular prodrome that result in clinical AD (Conejero-Goldberg et al., 2011). 
The broadly supported finding that carrying APOE4 allele is a risk factor of AD was 
replicated. Nevertheless, it was shown here that APOE4 and MAPT haplotypes do not act on 
synergy in Alzheimer’s disease in the Hungarian population. This part of the work also draws 
attention to the importance of validation of true epistasis. As it was discussed earlier by 
Combarros et al., and can be observed in this study too, a combined analysis based solely on 
χ2 test could have led to a false positive façade of gene interaction. However, the conclusions 
that can be drawn from this study must be tempered with the limitations imposed by statistical 
power arising from sample size and haplotype frequency.  
As tauopathies are multifactorial disorders, the role of environmental factors and epigenetic 
effects on the genome are also considerable (McCulloch et al., 2008). These can influence 
gene expression (Caffrey et al., 2006), alternative splicing (Andreadis, 2005) or both and may 
lead to enhanced tangle formation and disease development. The above mentioned population 
genetic effect is particularly interesting since the frequency of tauopathies is not elevated in 
East Asians or Africans where the H1 haplotype is almost obligate. 
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CONCLUSIONS 
This work encompasses studies which were born together with the research field of genomic 
inversion behind phenotypic variance. An outlook to populations characterized by a founder 
effect can be a medical researchers’ tool to shine more light on complex nature of 
multifactorial disorders. In Hungary, studying genetic variants related to mendelian disorders 
already shown success within Roma populations. Their unique genomic heritage could 
provide medical information to help studying structural variants. This project demonstrated 
that as the result of genetic admixture, 17q21.31 H2 haplotype appeared in Roma populations, 
and spread to ~10% even in the closed societies. Roma population therefore carries the 
Koolen De Vries syndrome associated genomic variant and Roma individuals are at risk to 
develop the disease. In our second study we demonstrated that dopamine transporter VNTR 
variants which were shown to be associated to addictive behavior (among other 
neuropsychiatric disturbances) are present with notably different frequencies in Hungarians 
and Roma. This result may have biological implications regarding therapeutic interventions 
for addictive disorders in Roma populations. Our third study examined H1 haplotype in 
Hungarian Alzheimer’s disease patients and studied genetic interactions with APOE4. H1 is 
not associated to AD in Hungarian populations while APOE4 is confirmed again. Together 
with other findings this result suggests the notion that 17q21.31 inversion H1 haplotype 
should be further studied in disorders where tauopathy is the major pathomechanism. 
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